Today's News | Note: News feeds may no longer be available for the articles on this page.

Pfizer's future tied to biotechnology 5:11 AM 2/12/2009
Chicago Tribune - United States
The world's largest drug company focuses on biotechnology-derived vaccines and drugs that target cancer and Alzheimer's. It's a change from routine maintenance pills for cholesterol, blood pressure, and depression. ...

Novartis Buys Rights to a Drug to Thin Blood 5:01 AM 2/12/2009
New York Times - United States
Portola Pharmaceuticals' Elinogrel is still in Phase 2 of clinical trials. Pending success in Phase 3, it couldn't hit the market before 2013. ...

Bone Drugs May Reduce Breast Cancer Recurrence 2:21 AM 2/12/2009
New York Times - United States
Patients who took Zometa (zoledronic acid) had a 36 percent reduction in cancer recurrences and metastases. ...

Oscient Pharmaceuticals cuts 1 third of employees 12:01 AM 2/12/2009
Forbes - NY,USA
Oscient Pharmaceuticals Corp will reduce staff from 300 to 200 in an effort to save cash and reduce its debt. ...

Peregrine drug meets goal in breast-cancer study 9:44 AM 2/11/2009
Reuters - USA
Peregrine Pharmaceuticals Inc's experimental cancer drug bavituximab met the main trial goal in a mid-stage study evaluating response in breast cancer patients. ...

Investor likely to sell Zentiva stake to Sanofi -source 7:47 AM 2/11/2009
Reuters - USA
Private shareholder Belviport Trading Ltd will likely sell its 10% stake in Czech drugmaker Zentiva to Sanofi-Aventis. ...

A Birth Control Pill That Promised Too Much 5:29 AM 2/11/2009
New York Times - United States
Those new, corrective Yaz ads on TV are just about as dumb as the regulators that asked for them. Do they really think the US consumer understands the revised message? And FDA… a little more attention to salmonella and less to pimples. ...

FDA delays decision on J&J drug for mood disorder 4:29 PM 2/10/2009
Forbes - NY,USA
Janssen Pharmaceuticals said that the US FDA has delayed making a decision on the company's drug Risperdal Consta for patients with bipolar disorder. ...

Par Pharmaceutical loses $70M court judgment 1:59 PM 2/10/2009
Forbes - NY,USA
Par Pharmaceutical Cos has been ordered to pay nearly $70 million dollars to Pentech Pharmaceuticals for breaching the companies' contract for supplying and marketing a generic version of Paxil (paroxetine). ...

Teva aims to launch generic version of Cubist drug 12:55 PM 2/10/2009
Forbes - NY,USA
Cubist's patents on Cubicin that don't expire until 2016 and 2019, but Teva asserts that those patents are either invalid or aren't infringed by its version. ...

Cougar, FDA agree on prostate cancer drug study design 10:46 AM 2/10/2009
Reuters - USA
Cougar Biotechnology Inc reached an agreement with the US FDA on the design for the late-stage clinical trial of its experimental drug CB7630 to treat prostate cancer. ...

Dyax grants Fovea eye-care formulation drug rights 8:32 AM 2/10/2009
Forbes - NY,USA
Dyax Corp granted licensing rights for the eye-treatment formulation of its developing drug DX-88 in the European Union. ...

Japan's Takeda, US Xoma to expand ties 6:38 AM 2/10/2009
Reuters - USA
Takeda Pharmaceutical Co and Xoma Ltd will expand their partnership to give Takeda access to Xoma's multiple antibody technologies. ...

Focus Stock: Smart Buys Boost Mylan 5:17 AM 2/10/2009
BusinessWeek - USA
Acquisitions of the generics division of Germany's Merck and India's API manufacturer Matrix Laboratories put Mylan on par with Teva. ...

Roche Formally Launches Hostile Tender for Genentech 3:17 AM 2/10/2009
Bloomberg - USA
Roche lowered its $89-a-share offer made in July taking the bid directly to shareholders. Roche already owns about 56 percent. ...

<- Day Earlier | Today's News